Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TOR Serine-Threonine Kinases”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Early research (Phase 1)Study completedNCT01548807
What this trial is testing

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Who this might be right for
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Abramson Cancer Center at Penn Medicine 19
Testing effectiveness (Phase 2)Study completedNCT00411619
What this trial is testing

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

Who this might be right for
Tuberous SclerosisSubependymal Giant Cell Astrocytoma
Children's Hospital Medical Center, Cincinnati 28
Not applicableStudy completedNCT01632605
What this trial is testing

The Vienna RAP Pilot Study

Who this might be right for
ADPKD
Medical University of Vienna 8
Post-approval studies (Phase 4)UnknownNCT03781050
What this trial is testing

Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome

Who this might be right for
Peutz-Jeghers Syndrome
Peking Union Medical College Hospital 10
Early research (Phase 1)Study completedNCT00999882
What this trial is testing

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Who this might be right for
CancerAdvanced Hepatocellular Carcinoma
AstraZeneca 26
Early research (Phase 1)Study completedNCT00574366
What this trial is testing

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT01070316
What this trial is testing

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Who this might be right for
EpilepsyTuberous Sclerosis Complex
Children's Hospital Medical Center, Cincinnati 20
Testing effectiveness (Phase 2)WithdrawnNCT01188889
What this trial is testing

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Who this might be right for
Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Post-approval studies (Phase 4)Study completedNCT01935128
What this trial is testing

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Who this might be right for
Renal Transplant
University of Toledo Health Science Campus 55
Early research (Phase 1)Study completedNCT01353625
What this trial is testing

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Who this might be right for
Glioblastoma MultiformeSquamous Cell Carcinoma of Head and NeckProstate Cancer+3 more
Celgene 118
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05285878
What this trial is testing

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Who this might be right for
Interstitial FibrosisKidney Transplant; ComplicationsKidney Transplant Rejection+4 more
The Methodist Hospital Research Institute 20
Post-approval studies (Phase 4)Study completedNCT01046045
What this trial is testing

Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients

Who this might be right for
Chronic Allograft Dysfunction in Renal Transplantation
Chinese University of Hong Kong 17
Early research (Phase 1)Study completedNCT00973076
What this trial is testing

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Who this might be right for
CancerSolid TumorsAdvanced Solid Malignancies
AstraZeneca 19
Testing effectiveness (Phase 2)Study completedNCT00353301
What this trial is testing

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
University of Colorado, Denver 25
Not applicableUnknownNCT03486366
What this trial is testing

Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children.

Who this might be right for
Epilepsy
Medical University of Warsaw 120
Testing effectiveness (Phase 2)UnknownNCT01960829
What this trial is testing

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

Who this might be right for
MelanomaTOR Serine-Threonine KinasesNeoplasm Metastasis
Peking University Cancer Hospital & Institute 60
Post-approval studies (Phase 4)UnknownNCT03767660
What this trial is testing

Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation

Who this might be right for
Blue Rubber Bleb Nevus SyndromeVenous Malformation
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)UnknownNCT02730923
What this trial is testing

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

Who this might be right for
Endometrial CarcinomaMetastatic CarcinomaHormone Receptor Positive Tumor
Centre Leon Berard 72
Testing effectiveness (Phase 2)Study completedNCT00331409
What this trial is testing

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Who this might be right for
Kidney Cancer
OHSU Knight Cancer Institute 23
Post-approval studies (Phase 4)Ended earlyNCT01561404
What this trial is testing

Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

Who this might be right for
Disorder Related to Renal TransplantationExercise, AerobicMuscle Strength
Josep M Cruzado 3
Load More Results